Ask HopeStage to review this study with me
Study ID: NCT07046494. We help you review the study, but cannot decide medical eligibility.
RecruitingNCT07046494
RAP-219 for manic episodes in bipolarity type I
This study is recruiting in the United States. It is testing RAP-219 for manic episodes in bipolarity type I.
BipolarityDrugFrom 18 Years to 65 Years
Key information made simple
What is this study testing?
This study is testing whether RAP-219 may be useful for adults experiencing bipolarity.
What would participation involve?
Participants may receive RAP-219, complete questionnaires or follow-up assessments, attend study visits with the research team. The protocol may also involve randomization, placebo, or a comparison group. The registry lists locations in United States.
Who is it mainly for?
This study appears to be mainly for adults with bipolarity.
What should you check before joining?
Ask about the dose, safety monitoring, and possible side effects, whether there is placebo, randomization, or a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.
Your next step
The official record suggests in-person participation through a hospital, with sites including Pillar Clinical Research - Little Rock, Woodland International Research Group in Little Rock, and Woodland Research Northwest in Rogers. Participation appears to involve a study treatment together with follow-up visits and routine safety or progress checks. The main fit is usually matching the main diagnosis and being able to follow the planned visits or tasks, while common reasons not to take part include active substance or alcohol problems that could affect the results and other factors that could make participation unsuitable. This is an early-stage study, which usually means a smaller group and a focus on learning how the approach behaves.
Questions to ask before joining
- What are the exact eligibility criteria, and what could exclude someone?
- How many visits, assessments, or follow-ups are expected, and over what period?
- What risks, side effects, practical burdens, or alternatives should be understood first?
- Who should be contacted to confirm locations, timing, compensation, and next steps?
Things to check before joining
Study start dateStarted: July 25, 2025
- Recruitment status
- Recruiting
- Estimated enrollment
- Not clearly listed
- Sponsor
- Rapport Therapeutics Inc.
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Medication / drug, OTHER
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT07046494
- Official title
- A Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of RAP-219 for the Acute Treatment of Manic Episodes, With or Without Mixed Features, Associated With Bipolar I Disorder
- Official source
- Official registry link
Want help reviewing this study?
Study ID: NCT07046494. We help you review the study, but cannot decide medical eligibility.
For you
Taking part may give access to a new approach being evaluated.
It requires regular visits and structured follow-up.
Requires travel, with in-person participation in United States.
Not medical advice
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com
Questions about this study
What is this study trying to understand?
This study is exploring medication or study treatment for people with bipolarity. Participants may complete study visits, assessments, or follow-up activities defined by the research team. It includes a comparison with placebo. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.
Does this study involve a medication?
This appears to be a medication / drug study involving RAP-219, Placebo. Phase 2 studies usually explore whether the intervention may work, while continuing to monitor safety.
Do I need to want to stop or reduce tobacco use to participate?
The public registry appears to mention tobacco, nicotine, alcohol, cannabis, or another addiction-related topic. Ask the study team whether you need to want to stop, reduce, already be abstinent, or simply meet use-related criteria. Eligibility must be confirmed by the study team.
What would I likely need to do?
You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
What side effects, interactions, or treatment changes should I check?
If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by Rapport Therapeutics Inc., which appears to be a biotech company. The listed contact or investigator is Rapport Therapeutics Inc., affiliated with Rapport Therapeutics Inc.. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The registry indicates that this study is currently recruiting. This does not mean you are eligible: the study team must confirm the criteria, available locations, and next steps.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
RecruitingNCT07172516
Azetukalner for depression in bipolarity
This study is recruiting in the United States. It is testing azetukalner for depression in bipolarity.
RecruitingNCT07286175
Brenipatide in adults with Bipolarity (RENEW-Bipolar-1)
This study is recruiting in the United States, in Argentina, in Brazil, .... It is testing brenipatide for Bipolarity.
RecruitingNCT06696755
Adverse Events and Change for Bipolarity
This study is recruiting in the United States. It is testing adverse Events and Change for Bipolarity.